Ilaprazole 10mg (EC) + Domperidone 30mg (SR)
ILAJOY DSR combines ilaprazole — the newest generation PPI — with domperidone SR in a dual-release capsule format.
Ilaprazole 10mg (Enteric Coated) is a fourth-generation proton pump inhibitor with a significantly improved pharmacological profile compared to all earlier PPIs. Like all PPIs, it irreversibly inhibits H⁺/K⁺-ATPase through acid-catalysed activation in the secretory canaliculus. Ilaprazole's clinical distinctions are:
1. CYP2C19-independent metabolism: Ilaprazole is metabolised primarily by CYP3A4 rather than CYP2C19, eliminating the inter-individual variability in acid suppression seen with omeprazole, pantoprazole, and lansoprazole in the 20% of South Asian patients who are rapid CYP2C19 metabolisers.
2. Longer plasma half-life: Ilaprazole has a plasma half-life of approximately 1.5–1.9 hours (longer than omeprazole's 0.5–1 hour) and more sustained acid-suppressive effects, providing 24-hour pH control from a single dose.
3. Higher acid-suppressive potency: Ilaprazole 10mg achieves intragastric pH >4 for a higher percentage of the 24-hour period compared to standard doses of omeprazole 20mg, pantoprazole 40mg, or rabeprazole 20mg.
4. Rapid onset: Despite oral dosing, ilaprazole achieves significant acid suppression within 2 hours of the first dose — faster than most other PPIs.
Domperidone 30mg SR: Same peripheral D2 receptor antagonism prokinetic mechanism as described in SOUNDRAB™ DSR.
GORD (particularly erosive oesophagitis requiring superior acid suppression), functional dyspepsia with delayed gastric emptying, laryngopharyngeal reflux, gastroparesis, and H. pylori eradication where maximum acid suppression (to optimise antibiotic efficacy at higher pH) is clinically required. Ilaprazole's CYP2C19-independent profile makes it the preferred PPI for patients who have experienced inadequate acid suppression with other PPIs and are suspected CYP2C19 rapid metabolisers.
Dosage and administration should be as prescribed by a qualified doctor or medical professional. Do not self-medicate. Always follow your physician's instructions regarding dose, frequency and duration of treatment.
Ilaprazole represents the most significant PPI pharmacological advance since esomeprazole. Its CYP2C19-independent metabolism directly addresses the single biggest limitation of existing PPIs — inter-individual variability driven by CYP2C19 polymorphism. The approximately 20% of Indian patients who are CYP2C19 rapid metabolisers consistently receive inadequate acid suppression from omeprazole, pantoprazole, and lansoprazole at standard doses. Ilaprazole eliminates this pharmacogenomic limitation entirely.
For gastroenterologists managing erosive oesophagitis, H. pylori eradication failure, and refractory GORD — conditions where maximum acid suppression is critical to clinical outcomes — ilaprazole's superior intragastric pH elevation translates directly to better mucosal healing rates, higher H. pylori eradication rates, and more reliable symptom control.
ILAJOY DSR at ₹2299 is positioned as the premium PPI-prokinetic combination — above pantoprazole-domperidone and rabeprazole-domperidone combinations — reflecting the clinical superiority of ilaprazole over these older PPIs. For franchise partners, the ilaprazole DSR segment is growing rapidly as specialist gastroenterologists adopt the newest PPI generation, and ILAJOY DSR positions Seclis Labs at the forefront of this premium GI prescription category.
Disclaimer: To be used under medical supervision only. Not intended for general public promotion. This content is meant for registered healthcare professionals only.